ToeFX Light Therapy for Chronic Venous Leg Ulcers

November 13, 2026 updated by: Dr. Ahmed Kayssi

Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study

Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.

A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.

The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.

This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.

The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.

Study Overview

Detailed Description

Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.

A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.

ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.

This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M4L 3Y3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or older
  • Able to attend weekly visits for up to 12 weeks
  • Chronic venous leg ulcer (CEAP C6) of the lower extremity
  • Ulcer duration of 4 weeks or more
  • Ulcer size between 1 cm² and 20 cm² at baseline
  • Receiving standard-of-care compression therapy, or eligible to initiate it
  • Able to provide informed consent and comply with study procedures

Exclusion Criteria:

  • Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
  • Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
  • Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
  • Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
  • Heavy exudate requiring negative-pressure wound therapy
  • Known photosensitivity or allergy to methylene blue or light-based therapies
  • Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
  • Pregnancy or lactation
  • Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
  • Participation in another interventional study within 30 days of screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Device Feasibility
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ToeFX Treatment

Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure

Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation

Other Names:
  • ToeFX
  • ClearToe Serum

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment adherence
Time Frame: Baseline through Visit 12/ end of treatment (up to 12 weeks)

Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions

Baseline through Visit 12/ end of treatment (up to 12 weeks)
Safety: Adverse Events
Time Frame: Baseline through Healing Confirmation Visit (up to 14 weeks)

Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs

Baseline through Healing Confirmation Visit (up to 14 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent Change in Wound Area From Baseline
Time Frame: Baseline, week 4, week 8, and week 12

Percent change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12
Complete wound epithelialization
Time Frame: 12 weeks

Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician

12 weeks
Time to complete wound healing
Time Frame: 12 weeks

Time (days) from baseline to complete epithelialization

12 weeks
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Time Frame: Baseline to 12 weeks/ end of treatment

Change in wound bed characteristics measured using the BWAT

Baseline to 12 weeks/ end of treatment
Change in pain score
Time Frame: Baseline to 12 weeks/ end of treatment

Change in pain score (0-10 Numeric Rating Scale)

Baseline to 12 weeks/ end of treatment
Change in health-related quality of life
Time Frame: 12 weeks/ end of treatment

Change in EQ-5D-5L score

12 weeks/ end of treatment
Patient satisfaction
Time Frame: 12 weeks/ end of treatment

Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire

12 weeks/ end of treatment
Clinician feasibility
Time Frame: 14 weeks or earlier if wound healing

Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow

14 weeks or earlier if wound healing
Absolute Change in Wound Area From Baseline
Time Frame: Baseline, week 4, week 8, and week 12

Absolute change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

October 31, 2027

Study Completion (Estimated)

October 31, 2027

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe